Zynex (ZYXI) to Release Earnings on Wednesday

Zynex (NASDAQ:ZYXI) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $53.65 million for the quarter.

Zynex Trading Up 2.4 %

Shares of ZYXI opened at $7.36 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex has a 12-month low of $7.12 and a 12-month high of $13.77. The firm has a market capitalization of $234.42 million, a PE ratio of 49.07 and a beta of 0.54. The stock’s fifty day simple moving average is $7.91 and its 200-day simple moving average is $8.04.

Insider Activity

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.08, for a total transaction of $80,800.00. Following the transaction, the chief financial officer now owns 35,190 shares of the company’s stock, valued at $284,335.20. This represents a 22.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 30,000 shares of company stock valued at $236,400 over the last 90 days. 52.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Zynex in a research note on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.